Healthineers Sets 2027 Profit Range as Buyback Passes 3.6 Million Shares

Siemens Healthineers closed the books on its 2026 fiscal year on Thursday with revenue of EUR 23.63 billion and adjusted earnings per share of EUR 2.42, pairing the results with a 2027 outlook and a planned corporate rebrand. The group's adjusted EBIT margin for the fourth quarter came in at 15.9%, according to company figures.

Fourth-quarter revenue rose 7.3% to EUR 6.78 billion, though Reuters reported that persistent weakness in China weighed on the diagnostics business. Comparable group sales grew 5.9% in the closing quarter, while Diagnostics slipped 4.2%. For the full 2026 fiscal year, comparable revenue growth reached 4.0%. The dividend is set to stay flat at EUR 1.00 per share.

2027 Targets and a New Name

Management is guiding for comparable revenue growth of 4.0% to 5.0% in fiscal 2027, with adjusted unadjusted earnings per share seen in a range of EUR 2.20 to EUR 2.40.

The company also announced on Thursday that it will rename itself Healthineers. Shareholder approval is required, and an extraordinary general meeting has been scheduled for 18 February 2027. The brand transition is due to begin after the Siemens spin-off is completed, with the start targeted for 2027 and the rollout spanning three years.

Analysts Split on Valuation

Barclays raised its price target to EUR 51 from EUR 47.50 on Friday, keeping its "Overweight" rating. UBS, by contrast, held its "Neutral" stance and a EUR 38 target on Thursday. Two further analyst notes published Thursday left their positive investment ratings unchanged, with price targets between EUR 48 and EUR 50. Deutsche Bank Research maintained a "Hold" rating and a EUR 39 target on Friday; analyst Falko Friedrichs called the fourth-quarter results mixed and pointed in particular to Precision Therapy.

Shares edged down 0.1% on Friday to close at EUR 44.70.

Buyback and Investor Calendar

On 2 November, Siemens Healthineers reported that it had repurchased 50,000 of its own shares between 26 October and 1 November inclusive under its buyback programme. Since the programme began on 1 June, roughly 3.6 million shares had been bought back through 1 November.

Investor relations activity continues apace: a roadshow with J.P. Morgan in London is scheduled for today, followed on 10 November by roadshows with UBS in Frankfurt and J.P. Morgan in Paris, according to the company calendar. Participation in the UBS European Healthcare Conference in London is also confirmed. The annual financial report for fiscal 2026 is due on 25 November.